Blockchain Registration Transaction Record

New Mpox Strain Emerges as GeoVax Accelerates First US-Made Vaccine

GeoVax responds to new recombinant Mpox strain with accelerated GEO-MVA vaccine program. EMA guidance allows direct Phase 3 trial for first US-made Mpox/smallpox vaccine.

The emergence of a recombinant Mpox strain demonstrates that viral threats continue to evolve, potentially increasing transmissibility or severity. This development exposes a critical weakness in global health security: over-reliance on a single vaccine manufacturer creates supply chain vulnerabilities that could leave populations unprotected during outbreaks. GeoVax's accelerated GEO-MVA program addresses this strategic gap by developing a domestically manufactured alternative that would diversify supply, enhance national biodefense capabilities, and potentially provide faster access to vaccines during public health emergencies. The streamlined EMA regulatory pathway could bring this important vaccine to market sooner, strengthening global preparedness against both Mpox and smallpox threats.